Schroder Investment Management Group Trims Stock Holdings in Zoetis Inc. $ZTS

Schroder Investment Management Group decreased its position in Zoetis Inc. (NYSE:ZTS) by 18.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 142,885 shares of the company’s stock after selling 32,865 shares during the quarter. Schroder Investment Management Group’s holdings in Zoetis were worth $22,283,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Brighton Jones LLC increased its stake in shares of Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in Zoetis by 13.8% in the first quarter. Commonwealth Equity Services LLC now owns 155,783 shares of the company’s stock worth $25,650,000 after purchasing an additional 18,868 shares during the period. ING Groep NV increased its stake in shares of Zoetis by 90.5% during the first quarter. ING Groep NV now owns 109,778 shares of the company’s stock valued at $18,075,000 after purchasing an additional 52,155 shares in the last quarter. Middleton & Co. Inc. MA lifted its holdings in shares of Zoetis by 1.7% during the first quarter. Middleton & Co. Inc. MA now owns 12,973 shares of the company’s stock valued at $2,136,000 after purchasing an additional 216 shares during the last quarter. Finally, New Age Alpha Advisors LLC boosted its position in shares of Zoetis by 119.0% in the 1st quarter. New Age Alpha Advisors LLC now owns 54,393 shares of the company’s stock worth $8,956,000 after purchasing an additional 29,555 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 2.2%

NYSE:ZTS opened at $124.44 on Wednesday. The company has a market cap of $54.84 billion, a PE ratio of 21.42, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The company has a 50 day simple moving average of $135.06 and a two-hundred day simple moving average of $148.47. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $181.85.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company’s revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st were given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.6%. The ex-dividend date of this dividend was Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is presently 33.67%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Morgan Stanley reduced their price objective on Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a research report on Monday, November 10th. BTIG Research reduced their price target on Zoetis from $200.00 to $160.00 and set a “buy” rating for the company in a report on Wednesday, November 12th. UBS Group dropped their price target on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Piper Sandler raised their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Finally, Stifel Nicolaus decreased their target price on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a report on Tuesday, November 18th. Six research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $178.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.